Cytori Therapeutics (NASDAQ: CYTX) has received notice from the Australian Therapeutic Goods Administration (TGA) that the Celution® System is approved for commercial use through inclusion on the Australian Registry of Therapeutic Goods for autologous re-implantation or re-infusion of a patient’s adipose-derived regenerative cells (ADRCs). The Celution® System produces autologous (a patient’s own) ADRCs at the point-of-care which may then be used for a range of injuries or conditions.
“Following an intensive two year review by the TGA, hospitals and physicians in Australia will have full commercial access to the only closed-system, point-of-care device which produces clinical-grade ADRCs for re-implantation or re-infusion into the patient,” said David C. Oxley, Vice President Emerging Markets for Cytori Therapeutics. “This approval establishes the foundation for enabling treatment of critical unmet medical needs across a variety of indications for patients in Australia.”
During the past two years, Dr. David Chin, MCh, PhD (Plast), FRCS, FRACS (Plast) of Queensland, Australia worked with Cytori under a TGA Authorized Prescriber Approval to treat a variety of conditions, particularly in the area of soft tissue injury and limited blood flow.
“We have had very favourable outcomes in the 80 plus patients treated using the Celution® System. Cases include breast reconstruction and patients who no longer wish to have silicone breast implants. Additional medical conditions, such as rheumatoid arthritis and soft tissue sports medicine related injuries are included,” commented Dr. Chin. “I can attest to the healing power of these cells based on the positive outcomes in my own clinical practice. In total, my experience includes a variety of presenting conditions over two years. Being able to access the patient’s own adipose derived regenerative cells during a single procedure opens up a whole dimension of acute and chronic medical conditions that may be addressed, including some previously considered untreatable under conventional treatment modalities.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV